SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2011 / Cilt: 21 - Sayı: 2

Kronik lenfositik lösemi ve kronik myelositer lösemi vakalarında çoklu ilaç direnç 1, akciğer direnç protein ve meme kanseri direnç protein genlerinin tanımlanması

Expression of multidrug resistance 1, lung resistance protein and breast cancer resistance protein genes in chronic leukemias

Özlem D. İŞERİ
Meltem D. KARS
PELİN MUTLU
Ferit AVCU
Ali U. URAL
Ufuk GÜNDÜZ
Pages
92–100
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MDR and LRP expressions seem to be frequent events in CLL and CML patients; however no conclusion can be drawn on their prognostic role and response to the treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:One of the major problems in treatment of leukemias is multidrug resistance, which is already present at diagnosis or develops after chemotherapy.
📊
Key Findings & Data:The gene expression levels of multidrug resistance resistance 1 (MDR1), breast cancer resistance protein (BCRP) and lung resistance-resistance protein (LRP) were evaluated in blood samples of 20 CLL and 24 CML patients using RT-PCR.
💡
Conclusion & Impact:MDR and LRP expressions seem to be frequent events in CLL and CML patients; however no conclusion can be drawn on their prognostic role and response to the treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

One of the major problems in treatment of leukemias is multidrug resistance, which is already present at diagnosis or develops after chemotherapy. The gene expression levels of multidrug resistance resistance 1 (MDR1), breast cancer resistance protein (BCRP) and lung resistance-resistance protein (LRP) were evaluated in blood samples of 20 CLL and 24 CML patients using RT-PCR. MDR1, BCRP and LRP expression levels were detected in 65%, 20% and 45% of CLL patients, and in 54%, 37% and 25% of CML patients, respectively. 20% of CLL patients and 33% of CML patients expressed none of the genes. The other 20% of CLL patients expressed all the genes. 17% of CML patients expressed all of these genes, and two of them rapidly progressed to acute leukemia. MDR and LRP expressions seem to be frequent events in CLL and CML patients; however no conclusion can be drawn on their prognostic role and response to the treatment.

Özet

Lösemi tedavisinde en önemli problemlerden birisi hastada zaten var olan veya kemoterapi sırasında gelişen, kemoterapötik ilaçlara karşı ilaç direncinin gelişmesidir. Çoklu ilaç dirençliliği genleri olan MDR1, BCRP, LRP gen ifadeleri 20 KLL ve 24 KML hastasında GT-PZR metoduyla belirlenmiştir. Çoklu ilaç dirençliliği genleri olan MDR1, BCRP, LRP gen ifadeleri 20 KLL ve 24 KML hastasında GT-PZR metoduyla belirlenmiştir. MDR1, BCRP ve LRP gen ifade düzeyleri KLL vakalarının sırasıyla %65, %20 ve %45’inde; KML vakalarının ise %54, %37 ve %25’inde bulunmuştur. KLL vakalarının %20’sinde ve KML vakalarının %33’ünde ise genlerin ifadeleri gözlenmemiştir. KLL hastalarının diğer %20’si ise incelenen genleri ifade etmişlerdir. KML hastalarının %17’si her üç geni ifade etmişler ve hastalardan ikisi akut lösemiye hızlı bir şekilde geçiş göstermişlerdir. MDR1 ve LRP gen ifadelerinin KLL ve KML için anlamlı olduğu anlaşılmaktadır. Ancak, gen ifadelerinin prognostik önemlerinin belirlenebilmesi açısından anlamlı bir sonuç çıkarılamamıştır.

🔖

Cite This Article

İŞERİ, Ö. D., KARS, M. D., MUTLU, P., AVCU, F., URAL, A. U., GÜNDÜZ, U. (2011). Kronik lenfositik lösemi ve kronik myelositer lösemi vakalarında çoklu ilaç direnç 1, akciğer direnç protein ve meme kanseri direnç protein genlerinin tanımlanması. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 21 - Sayı: 2, 92–100. https://ajindex.com/articles/323201

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34: 3-8, 1997
  2. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156-165, 1989
  3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993
  4. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021, 2000
  5. Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/ major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556, 2000
  6. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992
  7. Thiebaut F, Tsuruo T, Hamada Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in a multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37: 159, 1989
  8. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-Glycoprotein Expression and Function in Circulating Blood Cells From Normal Volunteers. Blood 83: 2451- 2458, 1994
  9. Chaudhary PM, Mechetner EB, Roninson lB. Expression and Activity of the Multidrug Resistance PGlycoprotein in Human Periphera1 Blood Lymphocytes. Blood 80: 2735-2739, 1992
  10. Chan LMS, Lowers S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51, 2004
  11. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance- related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9: 827-836, 2003
  12. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003
  13. Raaijmakersa M, de Grouwb E, Heuverb L, et al. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res 29: 1455-1458, 2005
  14. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr-110,000 vesicular protein in non- Pglycoprotein-mediated multidrug resistance. Can